Estrella Immunopharma Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.93 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.47Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $20.7M Enterprise Value $20.6M Shares Outstanding 43.2M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Estrella Immunopharma is a high-risk, high-reward clinical-stage biopharmaceutical company developing next-generation CD19 and CD22-targeted ARTEMIS T-cell therapies. While early Phase I data for its lead candidate, EB103, demonstrated an exceptional 100% complete response rate in aggressive B-cell Non-Hodgkin Lymphoma with a superior safety profile compared to traditional CAR-T therapies, the company faces severe financial constraints. With a persistent going concern warning, negative equity, and reliance on dilutive capital raises, the stock is best suited as a speculative Hold until Phase II clinical data provides further validation and the balance sheet is stabilized. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$12.00 Mean target$12.00 High · most bullish analyst$12.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $0.5020% Phase II clinical trials fail to replicate the high complete response rates of Phase I, or unexpected serious adverse events emerge. Furthermore, the company fails to raise sufficient capital, leading to a severe liquidity crunch, potential delisting from Nasdaq, or insolvency. Base CaseCentral scenario $8.0050% Estrella continues to advance EB103 through Phase II clinical trials at a measured pace. The company relies on periodic, dilutive PIPE financings and registered direct offerings to sustain operations, keeping the stock range-bound. The market remains cautious, balancing the promising early-stage clinical efficacy against ongoing liquidity risks and high share dilution. Bull CaseUpside scenario $12.0030% The proprietary ARTEMIS platform successfully overcomes the toxicity limitations of traditional CAR-T therapies (such as severe Cytokine Release Syndrome and ICANS) while maintaining high efficacy. EB103 achieves rapid regulatory approval following stellar Phase II results, and the company secures a lucrative licensing or co-development deal with a major pharmaceutical partner, driving the stock toward the consensus target. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |